Greater Glasgow and Clyde Medicines

Prescribing Notes:

• This class of medicines is not considered the most cost-effective choice when used as first-line therapy, and even when used as 2^nd or 3^rd line, they may only result in a modest reduction of HbA1c.  In some situations, alternative therapy, such as insulin or GLP-1 analogue may be more appropriate
• Patients initiated on gliptin therapy should be reviewed at 6 months and treatment should stop medication if individualised target not achieved AND HbA1c falls less than 0.5% (5.5mmol/mol). Please see the NHSGGC Type 2 Diabetes Guideline for further information (link here).

BNF Link

Restrictions:

It is restricted to use in patients for whom this fixed dose combination of alogliptin and metformin is an appropriate choice of therapy and only when the addition of a sulphonylurea to metformin monotherapy is not appropriate. Combination preparations are further restricted to use only in those patients who have demonstrable compliance issues with the separate constituents.

Prescribing Notes:

This class of medicines is not considered the most cost-effective choice when used as first-line therapy, and even when used as 2^nd or 3^rd line, they may only result in a modest reduction of HbA1c.  In some situations, alternative therapy, such as insulin or GLP-1 analogue may be more appropriate

Patients initiated on gliptin therapy should be reviewed at 6 months and treatment should stop medication if individualised target not achieved AND HbA1c falls less than 0.5% (5.5mmol/mol)

. Please see the NHSGGC Type 2 Diabetes Guidelines for further information (link here).

BNF Link